Epstein-Barr virus infection induces miR-21 in terminally differentiated malignant B cells.
Anastasiadou E et al. Int J Cancer. 2015 Feb 20. doi: 10.1002/ijc.29489. [Epub ahead of print].

BCL2L11/Bim as a dual-agent regulating autophagy and apoptosis in drug resistance.
Dai Y et al. Autophagy. 2015 Feb 20:0. [Epub ahead of print].

Hyaluronan synthase 1: a mysterious enzyme with unexpected functions.
Siiskonen H et al. Front Immunol. 2015 Feb 5;6:43. doi: 10.3389/fimmu.2015.00043. eCollection 2015.

BUB1B promotes multiple myeloma cell proliferation through CDC20/CCNB axis.
Yang Y et al. Med Oncol. 2015 Mar;32(3):542. doi: 10.1007/s12032-015-0542-x. Epub 2015 Feb 20.

Farnesol inhibits tumor growth and enhances the anticancer effects of bortezomib in multiple myeloma xenograft mouse model through the modulation of STAT3 signaling pathway.
Lee JH et al. Cancer Lett. 2015 Feb 16. pii: S0304-3835(15)00128-7. doi: 10.1016/j.canlet.2015.02.024. [Epub ahead of print].

PGC-1α is responsible for survival of multiple myeloma cells under hyperglycemia and chemotherapy.
Yu W et al. Oncol Rep. 2015 Feb 17. doi: 10.3892/or.2015.3809. [Epub ahead of print].

Mitochondrial genome of a spontaneous multiple myeloma bone cancer model mouse C57BL/KaLwRij strain.
Liu ZG et al. Mitochondrial DNA. 2015 Feb 19:1-2. [Epub ahead of print].

A simple flow cytometry-based barcode for routine authentication of multiple myeloma and mantle cell lymphoma cell lines.
Maïga S et al. Cytometry A. 2015 Feb 16. doi: 10.1002/cyto.a.22643. [Epub ahead of print].

Inhibitors of the AAA+ Chaperone p97.
Chapman E et al. Molecules. 2015 Feb 12;20(2):3027-3049.

Racial differences in primary cytogenetic abnormalities in multiple myeloma: a multi-center study.
Greenberg AJ et al. Blood Cancer J. 2015 Feb 13;5:e279. doi: 10.1038/bcj.2015.8.

CD4+ T cells in chronic autoantigenic stimulation in MGUS, multiple myeloma and Waldenström’s macroglobulinemia.
Neumann F et al. Int J Cancer. 2015 Feb 11. doi: 10.1002/ijc.29478. [Epub ahead of print].

Synergistic combination therapy with cotylenin A and vincristine in multiple myeloma models.
Takahashi T et al. Int J Oncol. 2015 Feb 9. doi: 10.3892/ijo.2015.2882. [Epub ahead of print].

Angiogenic markers in plasma cell myeloma patients treated with novel agents.
Medinger M et al. Anticancer Res. 2015 Feb;35(2):1085-90.

In vitro efficacy of cinnarizine against lymphoma and multiple myeloma.
Schmeel LC et al. Anticancer Res. 2015 Feb;35(2):835-41.

Ricolinostat (ACY-1215) induced inhibition of aggresome formation accelerates carfilzomib-induced multiple myeloma cell death.
Mishima Y et al. Br J Haematol. 2015 Feb 23. doi: 10.1111/bjh.13315. [Epub ahead of print].

BiTE-hIgFc-based Immunotherapy as a New Therapeutic Strategy in Multiple Myeloma.
Zou J et al. Cancer Sci. 2015 Feb 9. doi: 10.1111/cas.12631. [Epub ahead of print].

Genetics in myeloma: genetic technologies and their application to screening approaches in myeloma.
Talley PJ et al. Br Med Bull. 2015 Feb 6. pii: ldu041. [Epub ahead of print].

Niche-Based Screening in Multiple Myeloma Identifies a Kinesin-5 Inhibitor with Improved Selectivity over Hematopoietic Progenitors.
Chattopadhyay S et al. Cell Rep. 2015 Feb 4. pii: S2211-1247(15)00030-3. doi: 10.1016/j.celrep.2015.01.017. [Epub ahead of print].

PSMB4 promotes multiple myeloma cell growth by activating NF-κB-miR-21 signaling.
Zheng P et al. Biochem Biophys Res Commun. 2015 Feb 3. pii: S0006-291X(15)00149-7. doi: 10.1016/j.bbrc.2015.01.110. [Epub ahead of print].

MDX-1097 induces antibody-dependent cellular cytotoxicity against kappa multiple myeloma cells and its activity is augmented by lenalidomide.
Asvadi P et al. Br J Haematol. 2015 Feb 3. doi: 10.1111/bjh.13298. [Epub ahead of print].

The impact of clone size on the prognostic value of chromosome aberrations by fluorescence in situ hybridization in multiple myeloma.
An G et al. Clin Cancer Res. 2015 Feb 4. pii: clincanres.2576.2014. [Epub ahead of print].

Constitutive activation of p38 MAPK in tumor cells contributes to osteolytic bone lesions in multiple myeloma.
Yang J et al. Leukemia. 2015 Feb;29(2):515. doi: 10.1038/leu.2014.265.

Using digital polymerase chain reaction to detect minimal residual disease in myeloma by identifying FGFR3 up-regulation.
McAuliffe S et al. Leuk Lymphoma. 2015 Feb 17:1-3. [Epub ahead of print].

Whole-epigenome analysis in multiple myeloma reveals DNA hypermethylation of B cell-specific enhancers.
Agirre X et al. Genome Res. 2015 Feb 2. pii: gr.180240.114. [Epub ahead of print].

Immunophenotypic features by multiparameter flow cytometry can help distinguish low grade B-cell lymphomas with plasmacytic differentiation from plasma cell proliferative disorders with an unrelated clonal B-cell process.
Rosado FG et al. Br J Haematol. 2015 Feb 2. doi: 10.1111/bjh.13303. [Epub ahead of print].

Importin β1 mediates nuclear factor-κB signal transduction into the nuclei of myeloma cells and affects their proliferation and apoptosis.
Yan W et al. Cell Signal. 2015 Apr;27(4):851-9. doi: 10.1016/j.cellsig.2015.01.013. Epub 2015 Jan 30.

The tumor microenvironment shapes hallmarks of mature B-cell malignancies.
Shain KH et al. Oncogene. 2015 Feb 2. doi: 10.1038/onc.2014.403. [Epub ahead of print].

Canonical Wnt Pathway Inhibitor ICG-001 Induces Cytotoxicity of Multiple Myeloma Cells in Wnt-Independent Manner.
Grigson ER et al. PLoS One. 2015 Jan 30;10(1):e0117693. doi: 10.1371/journal.pone.0117693. eCollection 2015.

Targeting PD1-PDL1 immune checkpoint in plasmacytoid dendritic cell interactions with T cells, natural killer cells and multiple myeloma cells.
Ray A et al. Leukemia. 2015 Jan 30. doi: 10.1038/leu.2015.11. [Epub ahead of print].

Correlation between microRNA‑21 and sprouty homolog 2 gene expression in multiple myeloma.
Wang JH et al. Mol Med Rep. 2015 Jan 29. doi: 10.3892/mmr.2015.3280. [Epub ahead of print].

PAX5-positive plasma cell myeloma with t(9;14;11)(p13;q32;q13), a novel complex variant translocation of t(11;14)(q13;q32) and t(9;14)(p13;q32).
Sato K et al. Int J Hematol. 2015 Jan 30. [Epub ahead of print].